GlassScriptPhysician profile
Samuel O Etchie
NPI 1124039052
$74,248.96
in general payments reported to CMS, 2019-2025
18 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,867 · 2021: $4,773 · 2022: $6,662 · 2023: $1,848 · 2024: $23K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $9,435 · Consulting Fee: $4,040 · Travel and Lodging: $2,655 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,649.00 |
| Food and Beverage | $9,435.06 |
| Consulting Fee | $4,040.00 |
| Travel and Lodging | $2,654.68 |
| Education | $299.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $43,324.44 | 2019-2025 | Uzedy, Austedo Xr |
| Allergan, INC. | $8,848.55 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $6,141.11 | 2019-2025 | Ingrezza |
| Abbvie INC. | $6,136.98 | 2021-2025 | |
| Alkermes, INC. | $3,040.73 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $1,504.69 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $880.23 | 2019-2025 | Nuplazid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $743.80 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $702.55 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $588.85 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $583.73 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $572.36 | 2022-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $543.08 | 2019-2025 | Invega Sustenna |
| Neuronetics, INC. | $383.95 | 2019 | |
| Avanir Pharmaceuticals, INC. | $125.96 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $91.11 | 2023-2024 | Perseris |
| Lundbeck LLC | $36.84 | 2024-2025 | Rexulti |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Etchie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.